8-K: Syndax Pharmaceuticals Reports Q2 2024 Financials, Provides Pipeline Update

Syndax Pharmaceuticals announced its second quarter 2024 financial results and provided updates on its clinical pipeline, including upcoming PDUFA dates for axatilimab and revumenib.

Summary

• Syndax Pharmaceuticals reported its financial results for the second quarter of 2024, ending June 30, 2024.
• The company's cash, cash equivalents, and investments totaled $454.6 million.
• Research and development expenses for the quarter increased to $48.7 million, up from $34.8 million in the same period last year.
• Selling, general, and administrative expenses rose to $29.1 million, compared to $14.9 million in the prior year's quarter.
• The net loss attributable to common stockholders was $68.1 million, or $0.80 per share, compared to a net loss of $44.6 million, or $0.64 per share, in the same quarter of 2023.
• The company expects third quarter 2024 research and development expenses to be between $70 and $75 million and total operating expenses to be between $105 and $110 million.
• For the full year 2024, research and development expenses are projected to be $240 to $260 million, and total operating expenses are expected to be $355 to $375 million.
• Syndax anticipates having sufficient capital to fund operations through 2026.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant clinical progress and upcoming regulatory milestones. However, the increased losses and the delay in the revumenib PDUFA date temper the overall sentiment.

Positives

• The company has two key drug candidates, axatilimab and revumenib, with upcoming PDUFA dates.
• The BEAT AML trial showed a very high 96% composite complete remission rate for revumenib in combination therapy.
• The company has a strong cash position of $454.6 million, which is expected to fund operations through 2026.
• Syndax is advancing multiple clinical trials for revumenib in various combinations and indications.
• Axatilimab is showing positive results in treating chronic GVHD, with responses noted in multiple organs.
• The company is expanding its research into new indications and combinations for both axatilimab and revumenib.

Negatives

• The company reported a net loss of $68.1 million for the second quarter of 2024, which is an increase from the $44.6 million loss in the same period last year.
• Research and development expenses and selling, general, and administrative expenses have increased significantly compared to the prior year.
• The PDUFA date for revumenib was extended from September 26, 2024 to December 26, 2024.

Risks

• Clinical trial results may not be as positive as expected.
• Regulatory approvals for axatilimab and revumenib are not guaranteed.
• The company may face unexpected safety or efficacy issues during clinical trials.
• There is a risk of changes in the regulatory environment.
• The company's collaborators may not support or advance collaborations or product candidates as expected.
• The company may face unexpected litigation or other disputes.

Future Outlook

The company anticipates potential approval of both axatilimab and revumenib, and expects to report topline data from the AUGMENT-101 trial in the fourth quarter of 2024, which could support a supplemental NDA filing in the first half of 2025. Syndax believes it has sufficient capital to fund operations through 2026.

Management Comments

• Michael A. Metzger, Chief Executive Officer, stated that this is an exciting time for Syndax as they transition to a commercial stage company.
• He also noted significant progress in advancing the pipeline this quarter, including the presentation of updated revumenib and axatilimab data at EHA.

Industry Context

Syndax is operating in the competitive biopharmaceutical industry, focusing on oncology therapies. The company's progress with axatilimab and revumenib, particularly in areas like leukemia and GVHD, positions it to potentially address unmet medical needs. The use of the Real-Time Oncology Review program by the FDA reflects a broader trend towards accelerating the approval of promising cancer treatments.

Comparison to Industry Standards

• Syndax's 96% composite complete remission rate in the BEAT AML trial is very high compared to typical remission rates in AML treatments, which often range from 40-70% depending on the specific treatment and patient population.
• The 52% CRc rate in the AUGMENT-102 trial is also competitive, though it is important to note that this is in a relapsed/refractory setting, where response rates are generally lower.
• Companies like Agios Pharmaceuticals and Kura Oncology are also developing targeted therapies for AML, and their results will be important to compare with Syndax's.
• In the GVHD space, companies like Kadmon (now part of Sanofi) have developed treatments like belumosudil, and the efficacy and safety of axatilimab will be compared to these existing therapies.
• The financial metrics show a significant increase in R&D and SG&A expenses, which is typical for a company transitioning to commercialization. The cash position of $454.6 million is relatively strong for a company of this stage, but it will be important to monitor the burn rate as the company moves closer to potential product launches.

Management Changes

Stakeholder Impact

• Shareholders may see potential gains from positive clinical trial results and regulatory approvals.
• Employees may benefit from the company's growth and potential commercial success.
• Patients may gain access to new treatment options for cancer and fibrotic diseases.
• Suppliers and partners may see increased business opportunities.
• Creditors may have increased confidence in the company's financial stability.

Next Steps

• The company will continue to advance its clinical trials for revumenib and axatilimab.
• Syndax will report topline data from the AUGMENT-101 trial in the fourth quarter of 2024.
• The company will prepare for potential commercial launches of axatilimab and revumenib.
• Incyte will initiate two combination trials with axatilimab in earlier lines of treatment for chronic GVHD in the second half of 2024.
• Syndax plans to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy by year-end 2024.

Key Dates

Keywords

Syndax Pharmaceuticals, axatilimab, revumenib, cancer therapy, leukemia, GVHD, clinical trials, PDUFA, FDA, biopharmaceutical